For 29 stage II and 31 stage III colon cancer samples, mutation analysis of APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, BRAF and NRAS passed quality control (Supplementary Table S3). This evidence concerns the gene NRAS and malignant colon neoplasm.